Organigram Global Inc. announced the launch of its Edison and BOXHOT medical cannabis vape and pastille products in Australia, adding 10 new SKUs that feature single‑strain live terpenes and high‑volume cartridges designed for consistent dosing.
The new line will be distributed through Leafio, the wholesale arm of Montu Australia, giving Organigram access to more than 4,000 pharmacies nationwide and positioning the company to meet the growing demand for ready‑to‑consume medical cannabis formats.
This launch is a key step in Organigram’s strategy to diversify revenue beyond Canada and the United States. By entering a market valued at AUD 500‑700 million in 2025 and projected to expand further, the company aims to capture higher margins and lower excise‑tax exposure while supporting its proposed acquisition of Germany’s Sanity Group.
"Australia represents an exciting international opportunity in medical cannabis, and we are entering the market at a pivotal moment with an informed strategy. The launch of Organigram brands in Australia coincides with our proposed acquisition of Sanity Group, one of Germany's leading cannabis companies, marking a significant step in our international expansion," said Megan McCrae, Senior Vice President, Corporate Strategy & International Growth.
"Australia is a rapidly evolving medical market where we see momentum in ready‑to‑consume formats beyond traditional flower. As patient and clinician preferences continue to move toward reliable, convenient, non‑flower options that are grounded in science, data, and rigorous quality standards, Organigram is well‑positioned to participate in this next phase of growth," added Borna Zlamalik, Senior Vice President, Innovation and International R&D.
Organigram will debut the new products at the United in Compassion medical cannabis symposium in Brisbane on February 26‑28, a key industry event that attracts clinicians, regulators, and investors and provides a platform to showcase the company’s science‑led product portfolio.
The launch marks a significant operational milestone for Organigram, reinforcing its commitment to broadening its global reach and delivering consistent quality and reliability to patients across Australia and beyond.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.